|Bid||24.75 x 1400|
|Ask||24.98 x 1300|
|Day's Range||23.00 - 25.07|
|52 Week Range||1.94 - 28.70|
|Beta (3Y Monthly)||2.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors seeking stocks with high reward potential might want to consider this pharmaceutical company, oil and gas driller, and wind blade maker instead of wading into the high-risk penny stock market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arena Pharmaceuticals, ...
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
This startup has rapidly developed two potential blockbusters that are close to the finish line, and hardly anybody's noticed yet.
On a per-share basis, the New York-based company said it had a loss of 32 cents. Axsome shares have increased sixfold since the beginning of the year. The stock has risen fivefold in the last 12 months. ...
Here are four stocks to watch with strong technical momentum fueled by earnings and other news. Axsome Therapeutics, Inc. (NASDAQ: AXSM ) gained 39 cents to $19.54 on Tuesday on 1.4 million shares. The ...
Fuel Tech's (FTEK) Q1 results are likely to benefit from increased adoption of emission control solutions, efforts to improve sales channel and addition of a coal-fired unit in the United States.
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
Axsome Therapeutics Inc (NASDAQ: AXSM) has been a standout performer among biotech stocks year-to-date. Axsome announced Monday that the FDA granted Breakthrough Therapy Designation for its AXS-05, which is being evaluated for major depressive disorder, or MDD, and treatment-resistant depression, or TRD. With the expedited development program, the company said its previously completed ASCEND Phase 2 trial is adequate to file an NDA for MDD.